ViewRay Inc Stock News

CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, February 24, 2022 at 4:30 p.m. ET. The

ViewRay <> has extended gains for the second straight session after the company reported preliminary financial and operational data for Q4 and full-year 2021.Arguing that

ViewRay (VRAY) reports fourth preliminary revenue to be $20M in line with consensus.Full year revenue stands at $70M primarily from ten revenue units. The company received even new…

The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Earnings and Valuation This table compares CONMED and ViewRays top-line revenue, earnings per share and valuation. Gross Revenue [] The post Contrasting CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) appeared first on ETF Daily News .

CLEVELAND, Dec. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. ViewRay''s management is currently scheduled to present at 10:30 a.m. Eastern Time on Thursday, January 13, 2022. An audio webcast

Cedar Brook Financial Partners LLC lessened its stake in shares of ViewRay, Inc. (NASDAQ:VRAY) by 9.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,000 shares of the companys stock after selling 2,391 shares during the period. Cedar Brook Financial Partners LLCs holdings in ViewRay were []

The trading price of ViewRay Inc. (NASDAQ:VRAY) closed lower on Friday, December 10, closing at $5.41, -3.05% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Equities research analysts expect that ViewRay, Inc. (NASDAQ:VRAY) will announce sales of $20.14 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for ViewRays earnings, with estimates ranging from $19.40 million to $21.35 million. ViewRay reported sales of $18.46 million during the same quarter last year, which suggests a []

Wall Street brokerages forecast that ViewRay, Inc. (NASDAQ:VRAY) will report earnings per share of ($0.16) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for ViewRays earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.14). ViewRay reported earnings of ($0.18) per share in the same quarter last year, []

Joel Isaacson & Co. LLC boosted its holdings in ViewRay, Inc. (NASDAQ:VRAY) by 17.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 204,000 shares of the companys stock after acquiring an additional 30,000 shares during the period. Joel Isaacson & Co. []

ViewRay, Inc. (NASDAQ:VRAY) gapped up prior to trading on Friday . The stock had previously closed at $4.89, but opened at $5.20. ViewRay shares last traded at $5.10, with a volume of 2,371 shares. Several brokerages have recently weighed in on VRAY. B. Riley began coverage on ViewRay in a report on Thursday, October 14th. [] The post ViewRay (NASDAQ:VRAY) Shares Gap Up to $4.89 appeared first on ETF Daily News .

In last trading session, ViewRay Inc. (NASDAQ:VRAY) saw 1.37 million shares changing hands with its beta currently measuring 0.73. Companys recent per share price level of $4.89 trading at -$0.25 or -4.86% at ring of the bell on the day assigns it a market valuation of $777.36M. That closing price of VRAYs stock is at ViewRay Inc. (NASDAQ:VRAY) Stock Jumped 28.01% Year-To-Date, What Analysts Expect Next? Read More »